KALVISTA PHARMACEUTICALS
KalVista Pharmaceuticals is an ophthalmology company with a focus on diabetic macular edema (DME). KalVista is developing novel plasma kallikrein inhibitors, which represents a new approach to the treatment of DME, a leading cause of adult visual loss in developed countries. KalVista has an advanced pre-clinical product pipeline resulting from over 20 years of leading pharmaceutical discovery in the field of serine protease inhibitors and is targeting both intravitreal injection and oral adminis... tration. Although VEGF inhibitors clearly can benefit DME, a significant number of patients do not respond fully to these agents and have limited treatment options. Plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option.
KALVISTA PHARMACEUTICALS
Industry:
Biotechnology Diabetes Health Care
Founded:
2011-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.kalvista.com
Total Employee:
11+
Status:
Active
Contact:
(857) 999 0075
Email Addresses:
[email protected]
Total Funding:
239.7 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Google Tag Manager Google Universal Analytics Global Site Tag Nginx
Similar Organizations
Gelesis
Gelesis is a biotechnology company developing first-in-class therapeutics to safely treat obese, overweight, and diabetic patients.
Milestone Pharmaceuticals
Milestone Pharmaceuticals is a drug development company developing small molecule therapeutics for the treatment of cardiovascular diseases.
NovaBay Pharmaceuticals
NovaBay Pharmaceuticals is a biopharmaceutical company developing products for the eye care market.
Ribon Therapeutics
Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2016-06-15 | Carbylan Therapeutics | Carbylan Therapeutics acquired by KalVista Pharmaceuticals | N/A |
Investors List
Longwood Fund
Longwood Fund investment in Series B - KalVista Pharmaceuticals
Venrock
Venrock investment in Series B - KalVista Pharmaceuticals
Novo Holdings
Novo Holdings investment in Series B - KalVista Pharmaceuticals
SV Health Investors
SV Health Investors investment in Series B - KalVista Pharmaceuticals
RA Capital Management
RA Capital Management investment in Series B - KalVista Pharmaceuticals
Novo Holdings
Novo Holdings investment in Series A - KalVista Pharmaceuticals
SV Health Investors
SV Health Investors investment in Series A - KalVista Pharmaceuticals
Key Employee Changes
| Date | New article |
|---|---|
| 2021-05-03 | KalVista bulks up executive team with CMO addition as angioedema franchise grinds to launch |
Official Site Inspections
http://www.kalvista.com Semrush global rank: 1.92 M Semrush visits lastest month: 11.32 K
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "KalVista Pharmaceuticals"
About Us - KalVista Pharmaceuticals
KalVista Pharmaceuticals is a biopharmaceutical company discovering, developing and commercializing oral protease inhibitor drugs based on deep expertise in the kallikrein-kinin system. Our commitment to rigorous science is …See details»
KalVista Pharmaceuticals - Crunchbase Company …
KalVista Pharmaceuticals is an ophthalmology company with a focus on diabetic macular edema (DME). KalVista is developing novel plasma kallikrein inhibitors, which represents a new approach to the treatment of DME, a leading cause of …See details»
Board of Directors - KalVista Pharmaceuticals
Ben is the Chief Executive Officer and a director of KalVista. Since 2023, he served as the Company’s President, where he was given the responsibility for leading future business …See details»
KalVista Pharmaceuticals Company Profile - Office Locations ...
Oct 29, 2024 KalVista Pharmaceuticals has 5 employees across 2 locations and $12.69 m in annual revenue in FY 2020. See insights on KalVista Pharmaceuticals including office …See details»
Corporate Overview - ir.kalvista.com
**Gehan’s Generalized Wilcoxon Test Full analysis set / KalVista Phase 2 Sebetralstat Data Published in the Lancet, Feb 2023 Censoring occurs where HAE attack was not rated “a little …See details»
| KalVista Pharmaceuticals
Read more about KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) KalVista Pharmaceuticals …See details»
KalVista Appoints Jeb Ledell as Chief Operating Officer | KalVista ...
6 days ago CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--Dec. 16, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Jeb Ledell has joined …See details»
KalVista Pharmaceuticals - Contacts, Employees, Board Members, …
Organization. KalVista Pharmaceuticals . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. ... About. KalVista Pharmaceuticals has 7 current employee …See details»
KalVista Pharmaceuticals Highlights Strategic Plans for Coming …
May 1, 2024 CAMBRIDGE, Mass. & SALISBURY, England, May 01, 2024--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced its strategic plans for fiscal year …See details»
KalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board …
Nov 26, 2024 KalVista Pharmaceuticals, Inc. is a global pharmaceutical company whose mission is to develop and deliver life-changing oral medicines for people affected by rare diseases with …See details»
Senior Management - KalVista Pharmaceuticals
Rachel M. Morten Senior Vice President, Regulatory Affairs and QA Brian Piekos Chief Financial Officer Michael D. Smith, PharmD Senior Vice President of DevelopmentSee details»
KalVista Pharmaceuticals Ltd. - Drug pipelines, Patents ... - Patsnap
Nov 1, 2024 Explore KalVista Pharmaceuticals Ltd. with its drug pipeline, therapeutic area, technology platform, 19 clinical trials, 12 news, and 5 literature, Disease Domain:Immune …See details»
KalVista Pharmaceuticals Appoints New COO Amid Strategic Growth
5 days ago KalVista Pharmaceuticals, Inc. is a global pharmaceutical company focused on developing and delivering oral medicines for rare diseases with significant unmet needs. Their …See details»
KalVista Pharmaceuticals Reports First Fiscal Quarter Results and ...
Jul 31, 2024 About KalVista Pharmaceuticals, Inc. KalVista Pharmaceuticals, Inc. is a global pharmaceutical company focused on the development and delivery of oral medicines for …See details»
KalVista appoints Jeb Ledell as COO - Markets Insider
6 days ago KalVista announced that Jeb Ledell has joined the company as COO.Ledell has more than 20 years of leadership and operational experience in the biotechnology industry. He …See details»
Jeb Ledell - KalVista Pharmaceuticals
Jeb has more than 20 years of leadership experience delivering operational excellence in the biotechnology industry. He joins KalVista from AVEO Oncology, and LG Chem Company, …See details»
KalVista Pharmaceuticals | Cambridge MA - Facebook
KalVista Pharmaceuticals, Cambridge, Massachusetts. 9 likes · 51 talking about this. KalVista is advancing science to empower everyday lives with innovative oral medicines. Our mission …See details»
KalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to
Nov 26, 2024 CAMBRIDGE, Mass.& SALISBURY, England---- KalVista Pharmaceuticals, Inc., today announced that Laurence Reid, Ph.D., has been appointed to the Company’ s Board of …See details»
Breaking Down KalVista Pharmaceuticals, Inc. (KALV) Financial …
The debt-to-equity ratio is a critical metric for assessing KalVista's financial health. Currently, the company’s debt-to-equity ratio is approximately 0.15, which is significantly lower than the …See details»
Annual Meeting - KalVista Pharmaceuticals
KalVista FY24 10-K. 2024 Proxy Card. 2024 Proxy Statement. Pagination. Current page 1; Page 2; Next page › Last page ...See details»